4TEEN4 Pharmaceuticals GmbH
4TEEN4 Pharmaceuticals GmbH is a German biotech company pioneering precision medicine in critical care, with a mission to develop causal therapies for acute cardiovascular complications, particularly shock. The company focuses on targeting cDPP3, a key mediator in circulatory failure, and is advancing Procizumab, a first-in-class antibody, through clinical development. With a leadership team boasting over 150 years of pharma experience and a strong network of international researchers, 4TEEN4 aims to address unmet medical needs and improve patient outcomes where current therapies are inadequate.
Industries
Nr. of Employees
small (1-50)
4TEEN4 Pharmaceuticals GmbH
Neuendorfstrasse 15A, 16761 Hennigsdorf, Germany
Patents
DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
2022-12-20 • US-11530276-B2
View Details
DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
2022-12-20 • US-11530276-B2
View DetailsProducts
Clinical-stage monoclonal antibody inhibitor of circulating DPP3 (clinical candidate)
A humanized monoclonal antibody therapeutic candidate developed to bind and inhibit circulating dipeptidyl peptidase 3 (cDPP3); shown to modulate hemodynamics and RAAS-related peptide degradation in preclinical models and progressed through Phase 1 clinical evaluation.
Clinical-stage monoclonal antibody inhibitor of circulating DPP3 (clinical candidate)
A humanized monoclonal antibody therapeutic candidate developed to bind and inhibit circulating dipeptidyl peptidase 3 (cDPP3); shown to modulate hemodynamics and RAAS-related peptide degradation in preclinical models and progressed through Phase 1 clinical evaluation.
Expertise Areas
- Biomarker-driven therapeutics
- Monoclonal antibody development
- Cardiovascular critical care therapeutics
- Clinical trial management (Phase 1 to Phase 3)
Key Technologies
- Monoclonal antibody therapeutics
- Circulating protein biomarker assays
- Point-of-care immunoassay platforms (inferred)
- Preclinical animal efficacy models
Key People
News & Updates
Awarded to Adrien Picod for research on cDPP3 in circulatory failure, in collaboration with 4TEEN4.
Awarded to Florian A. Wenzl, MD, for research identifying cDPP3 as a biomarker of cardiogenic shock.
Coverage of 4TEEN4's new therapy for heart attack patients.
Article discussing 4TEEN4's approach to shock treatment.
Feature on 4TEEN4's innovative work in cardiovascular disease.
4TEEN4 successfully completed its Phase 1 clinical trial for Procizumab, confirming a favorable safety profile and preparing for further clinical trials in circulatory failure.
Awarded to Adrien Picod for research on cDPP3 in circulatory failure, in collaboration with 4TEEN4.
Awarded to Florian A. Wenzl, MD, for research identifying cDPP3 as a biomarker of cardiogenic shock.
Coverage of 4TEEN4's new therapy for heart attack patients.
Article discussing 4TEEN4's approach to shock treatment.
Feature on 4TEEN4's innovative work in cardiovascular disease.
4TEEN4 successfully completed its Phase 1 clinical trial for Procizumab, confirming a favorable safety profile and preparing for further clinical trials in circulatory failure.